Isomorphic Labs kicks off 2024 with two pharmaceutical collaborations

0
a--up
a--h-150-100
0
a--up
none
1
a--up
none
2
a--up
none
0
a--up
none
1
a--up
none
2
a--up
none

Isomorphic Labs announces strategic collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis. These partnerships have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties that may result from future drug sales, and are testament to Isomorphic’s approach to drug design and the progress we are making. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments.

Read more in the news releases below.

0
a--up
a--h-150-100
No items found.
a--up
2
2
1
0
a--up
none
0
a--up
none
0
a--up
a--h-150-100
0
a--up
none
No items found.
a--up
2
2
1
0
a--up
none
0
a--up
none
0
a--up
a--h-150-100
0
a--up
none

0
a--up
none
1
a--up
none
0
a--up
none
0
a--up
none
1
a--up
none

Eli Lilly

Isomorphic Labs to Receive $45 Million in Upfront Payment For Multi-Target Research Collaborations with Lilly
0
a--up
none

Novartis

Isomorphic Labs to Receive $37.5 Million Upfront Payment From Novartis to Collaborate on Small Molecule Therapeutics Discovery
1
a--up
none

0
a--up
none

0
a--up
none

0
a--up
none